Desentum: Funding, Investors & Team (Sep 2026)
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.
Desentum has raised $22.0M across 2 funding rounds on record, the most recent an undisclosed round of $12.9M announced in Feb 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Desentum Company Profile and Key Stats
Latest funding round on record: Feb 2024.
Desentum Funding Rounds
Desentum raised $9.1M in an undisclosed round announced in Jan 2022.
2.1 years later, an undisclosed round of $12.9M was announced in Feb 2024.
Desentum Founders and Leadership Team
No contact details are on record for this team yet.
Desentum Funding Compared to Other Biotechnology Startups
Desentum's latest round of $12.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Desentum in Biotechnology and Espoo
Companies Similar to Desentum
Solar Foods is a food-tech startup that focuses on utilizing a technology that involves using electricity to…
Algorithmiq utilizes its expertise in quantum information, complex systems, and computational physics to…
Bioretec Ltd. is a Finnish material technology company focused on the development, manufacturing and…
NPHarvest is a company with expertise in organic waste management, wastewater treatment, and nutrient…
They are a pioneering company driven by a passion for innovation and a commitment to solving their partners’…
StemSight is a startup focusing on cell therapy in Tampere, Finland, where they are working on innovative…
Herantis Pharma is a company focused on addressing medical needs that have not been met by current treatments.
Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and…
Eevia Health is a Nordic life science company based in Finland and Norway, with headquarters in Seinäjoki and…
Nexstim is a medical device company focused on image-guided transcranial magnetic stimulation, dedicated to…
Enifer is a company that specializes in using fungal fermentation to create products from byproducts of the…
Desentum Funding FAQs
What does Desentum do?
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.
How much funding has Desentum raised?
Desentum has raised $22.0M across 2 rounds on record. The most recent is an undisclosed round of $12.9M announced in Feb 2024.
When did Desentum last raise funding?
Desentum's most recent funding round on record is an undisclosed round of $12.9M, announced in Feb 2024.
Who founded Desentum?
FundedIQ lists Pekka Mattila (Founder) at Desentum.
Where is Desentum headquartered?
Desentum is based in Espoo, Southern Finland, Finland.
How many employees does Desentum have?
Desentum is in the 1-10 employee band.
How does Desentum's funding compare to other Biotechnology startups?
Desentum's latest round of $12.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Desentum Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Desentum is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.